Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Net Margin (2022 - 2025)

Historic Net Margin for Taysha Gene Therapies (TSHA) over the last 4 years, with Q2 2025 value amounting to 1353.58%.

  • Taysha Gene Therapies' Net Margin rose 5284400.0% to 1353.58% in Q2 2025 from the same period last year, while for Sep 2025 it was 1583.66%, marking a year-over-year decrease of 13539900.0%. This contributed to the annual value of 1071.62% for FY2024, which is 3495600.0% down from last year.
  • According to the latest figures from Q2 2025, Taysha Gene Therapies' Net Margin is 1353.58%, which was up 5284400.0% from 935.23% recorded in Q1 2025.
  • Taysha Gene Therapies' Net Margin's 5-year high stood at 7487.65% during Q1 2022, with a 5-year trough of 2467.07% in Q3 2023.
  • For the 4-year period, Taysha Gene Therapies' Net Margin averaged around 641.48%, with its median value being 817.21% (2024).
  • As far as peak fluctuations go, Taysha Gene Therapies' Net Margin plummeted by -78621100bps in 2023, and later surged by 10395500bps in 2024.
  • Taysha Gene Therapies' Net Margin (Quarter) stood at 4220.54% in 2022, then crashed by -69bps to 1324.67% in 2023, then tumbled by -170bps to 929.03% in 2024, then plummeted by -46bps to 1353.58% in 2025.
  • Its Net Margin stands at 1353.58% for Q2 2025, versus 935.23% for Q1 2025 and 929.03% for Q4 2024.